Etude des mécanismes cellulaires de transduction de signaux, à travers la caractérisation de deux gènes: le proto-oncogène MCF2/DBL et le gène FTL4 = Cell signal transduction through the study of two genes: MCF2/DBL proto-oncogene and FTL4 geneGalland, Franck; Birnbaum, Daniel.1992, 167 p.Thesis

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase InhibitorsMEYER, Sara C; LEVINE, Ross L.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2051-2059, issn 1078-0432, 9 p.Article

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-AnilinoquinazolinesSCHEFFLER, Matthias; DI GION, Paola; DOROSHYENKO, Oxana et al.Clinical pharmacokinetics. 2011, Vol 50, Num 6, pp 371-403, issn 0312-5963, 33 p.Article

Playing Russian Roulette With Tyrosine Kinase InhibitorsSZMULEWITZ, R. Z; RATAIN, M. J.Clinical pharmacology and therapeutics. 2013, Vol 93, Num 3, pp 242-244, issn 0009-9236, 3 p.Article

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and PyrrolesDI GION, Paola; KANEFENDT, Friederike; LINDAUER, Andreas et al.Clinical pharmacokinetics. 2011, Vol 50, Num 9, pp 551-603, issn 0312-5963, 53 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase InhibitorLICHUAN LIU; HALLADAY, Jason S; KUEBLER, Peter et al.Drug metabolism and disposition. 2011, Vol 39, Num 10, pp 1840-1849, issn 0090-9556, 10 p.Article

Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell deathIKEDA, Masahiro; GUNJI, Yasuhiro; SONODA, Hiroko et al.European journal of pharmacology. 2006, Vol 546, Num 1-3, pp 36-39, issn 0014-2999, 4 p.Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesLOVLY, Christine M; SHAW, Alice T.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2249-2256, issn 1078-0432, 8 p.Article

Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

Third-Generation Tyrosine Kinase Inhibitors and BeyondQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; CORTES, Jorge et al.Seminars in hematology. 2010, Vol 47, Num 4, pp 371-380, issn 0037-1963, 10 p.Article

Phosphorylation of small peptides by spleen TPK-IIA, a tyrosine protein kinase stimulated by polylysine and by high ionic strengthBRUNATI, A. M; MARCHIORI, F; RUZZA, P et al.FEBS letters. 1989, Vol 254, Num 1-2, pp 145-149, issn 0014-5793, 5 p.Article

Janus kinase inhibitors for the treatment of myeloproliferative neoplasmsROSENTHAL, Allison; MESA, Ruben A.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 9, pp 1265-1276, issn 1465-6566, 12 p.Article

Receptor tyrosine kinase signaling and trafficking: Paradigms revisitedBARBIERI, M. A; RAMKUMAR, T. P; FERNADEZ-POL, S et al.Current Topics in Microbiology and Immunology. 2004, Vol 286, pp 1-19, issn 0070-217X, 19 p.Article

Light-regulated sampling of protein tyrosine kinase activityQUNZHAO WANG; ZHAOHUA DAI; CAHILL, Sean M et al.Journal of the American Chemical Society. 2006, Vol 128, Num 43, pp 14016-14017, issn 0002-7863, 2 p.Article

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsPARDANANI, A; VANNUCCHI, A. M; PASSAMONTI, F et al.Leukemia. 2011, Vol 25, Num 2, pp 218-225, issn 0887-6924, 8 p.Article

Efficacy of ruxolitinib for myelofibrosisSANTOS, Fabio P. S; VERSTOVSEK, Srdan.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 10, pp 1465-1473, issn 1465-6566, 9 p.Article

A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndromeDE RAVEL, Thomy J. L; TAYLOR, Indira B; VAN OOSTVELDT, Alex J. T et al.European journal of human genetics. 2005, Vol 13, Num 4, pp 503-505, issn 1018-4813, 3 p.Article

RACK1 regulates src-mediated Sam68 and p190RhoGAP signalingMILLER, Laura D; LEE, Kelly C; MOCHLY-ROSEN, Daria et al.Oncogene (Basingstoke). 2004, Vol 23, Num 33, pp 5682-5686, issn 0950-9232, 5 p.Article

Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitorMACGLASHAN, Donald; HONIGBERG, Lee A; SMITH, Ashley et al.International immunopharmacology (Print). 2011, Vol 11, Num 4, pp 475-479, issn 1567-5769, 5 p.Article

Identification of the proteins present in the bull sperm cytosolic fraction enriched in tyrosine kinase activity : A proteomic approachLALANCETTE, Claudia; FAURE, Robert L; LECLERC, Pierre et al.Proteomics (Weinheim. Print). 2006, Vol 6, Num 16, pp 4523-4540, issn 1615-9853, 18 p.Article

Systemic therapy in neurofibromatosis type 2LIM, Stephanie Hui-Su; ARDERN-HOLMES, Simone; MCCOWAGE, Geoffrey et al.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 857-861, issn 0305-7372, 5 p.Article

Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agentYANTING ZHANG; YAQIONG ZHANG; SHENGRONG GUO et al.International journal of pharmaceutics (Print). 2009, Vol 369, Num 1-2, pp 19-23, issn 0378-5173, 5 p.Article